Εσθονία - Εσθονικά - Ravimiamet

meda pharma gmbh & co. kg - fentanüül - bukaalravimkile - 1200mcg 28tk; 1200mcg 4tk; 1200mcg 3tk; 1200mcg 10tk

Εσθονία - Εσθονικά - Ravimiamet

fresenius kabi deutschland gmbh - imatiniib - õhukese polümeerikattega tablett - 100mg 20tk; 100mg 10tk; 100mg 120tk; 100mg 60tk; 100mg 30tk

Εσθονία - Εσθονικά - Ravimiamet

meda pharma gmbh & co. kg - fentanüül - bukaalravimkile - 800mcg 4tk; 800mcg 10tk; 800mcg 28tk

Εσθονία - Εσθονικά - Ravimiamet

meda pharma gmbh & co. kg - fentanüül - bukaalravimkile - 600mcg 28tk; 600mcg 4tk; 600mcg 10tk

Εσθονία - Εσθονικά - Ravimiamet

meda pharma gmbh & co. kg - fentanüül - bukaalravimkile - 200mcg 1tk

Εσθονία - Εσθονικά - Ravimiamet

fresenius kabi deutschland gmbh - imatiniib - õhukese polümeerikattega tablett - 400mg 120tk; 400mg 90tk; 400mg 180tk; 400mg 20tk; 400mg 10tk; 400mg 60tk

Ευρωπαϊκή Ένωση - Εσθονικά - EMA (European Medicines Agency)

koanaa healthcare gmbh - imatinib mesilate - leukemia, myelogenous, chronic, bcr-abl positive; precursor cell lymphoblastic leukemia-lymphoma; myelodysplastic-myeloproliferative diseases; hypereosinophilic syndrome; dermatofibrosarcoma; gastrointestinal stromal tumors - antineoplastilised ained - imatinib koanaa is indicated for the treatment ofadult and paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment. adult and paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy. adult patients with relapsed or refractory ph+ all as monotherapy. adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements. adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfrα rearrangement. the effect of imatinib on the outcome of bone marrow transplantation has not been determined. imatinib koanaa is indicated forthe treatment of adult patients with kit (cd 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist). the adjuvant treatment of adult patients who are at significant risk of relapse following resection of kit (cd117)-positive gist. patsientidel, kellel on madal või väga madal risk kordumise ei tohiks saada abiaine ravi. the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic gist and dfsp and on recurrence-free survival in adjuvant gist. the experience with imatinib in patients with mds/mpd associated with pdgfr gene re-arrangements is very limited (see section 5. välja arvatud äsja diagnoositud kroonilise faasi cml, ei ole kontrollitud uuringud, mis näitab kliiniline kasu või suurenenud ellujäämise eest need haigused.

Ευρωπαϊκή Ένωση - Εσθονικά - EMA (European Medicines Agency)

laboratorios lesvi s.l. - dimetüülfumaraat - sclerosis multiplex, relapsing-remitting - immunosupressandid - dimethyl fumarate neuraxpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

Εσθονία - Εσθονικά - Ravimiamet

teva gmbh - pirfenidoon - õhukese polümeerikattega tablett - 801mg 252tk; 801mg 84tk

Εσθονία - Εσθονικά - Ravimiamet

teva gmbh - pirfenidoon - õhukese polümeerikattega tablett - 267mg 252tk